// App-Quantinova.ai

POS0608 (2021) : SWITCHING OF TREATMENT FROM REFERENCE ETANERCEPT TO SANDOZ ETANERCEPT BIOSIMILAR IN PATIENTS WITH RHEUMATIC DISEASES: AN INTERIM ANALYSIS OF REAL-WORLD DATA FROM THE COMPACT STUDY

Researchers

Presenter

  • M. Schmalzing

Principal Investigators

  • A. Askari

  • T. Sheeran

  • D. Walsh

  • F. Furlan

  • S. Hachaichi

  • H. Kellner

Medical Centers

  • University Hospital Würzburg, Rheumatology/Clinical Immunology, Department of Internal Medicine II, Würzburg, Germany

  • Robert Jones and Agnes Hunt Orthopedic Hospital NHS Foundation Trust, Department of Rheumatology, Oswestry, United Kingdom

  • Cannock Chase Hospital, Department of Rheumatology, Cannock, United Kingdom

  • University of Nottingham and Sherwood Forest Hospitals NHS Foundation Trust, Pain Centre Versus Arthritis, Nottingham, United Kingdom

  • University Hospital Coruña, Servicio de Reumatología, A Coruña, Spain

  • University Hospital Complex of Ferrol, Rheumatology Department, Ferrol, Spain

  • Sandoz Hexal AG, Global Medical Affairs, Holzkirchen, Germany

  • Hospital Neuwittelsbach, Center for Rheumatology and Gastroenterology, Munich, Germany

Locations

  • Germany

  • United Kingdom

  • Spain

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

  • Musculoskeletal

Disease

  • Ankylosing spondylitis

Biomarkers

  • N/A

Drug/Treatment

  • Etanercept biosimilar

  • Sandolase

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • Chugai/Roche

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved